TOMI Environmental Solutions, Inc. Reports Third Quarter 2020 Financial Results
November 12 2020 - 4:03PM
TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ:TOMZ), is a
global company specializing in disinfection and decontamination
utilizing its premier Binary Ionization Technology (BIT) platform
through its SteraMist brand of products - a hydrogen peroxide-based
mist and fog comprised of ionized Hydrogen Peroxide (iHP),
announced its results for the third quarter of 2020.
TOMI Chief Executive Officer, Dr. Halden Shane stated, “We are a
company that strives for SteraMist to become the gold standard in
its industry, and I report another major milestone with revenues
exceeding $21 million for our current calendar year. The third
quarter also continued the trend of year over year revenue growth
as SteraMist continues to see widespread adoption. We
have been pleasantly surprised to see that new clients in a number
of the new verticals targeted by our commercial division are
proving to be faster in integrating SteraMist into their protocol
compared to blue-chip clients that adhere to stringent protocol and
procedures. On the other hand, the TOMI Service Network and
Healthcare Divisions faced persistent headwinds in the quarter as a
number of potential clients elected to continue to utilize harsh
chemical disinfectants and low-cost delivery systems. We anticipate
these industries will increasingly see negative affects of these
disinfectants and increasingly seek SteraMist to be their permanent
solution, a trend that we have already seen as we begin the fourth
quarter, as many of these companies are our either returning to or
starting to use SteraMist. We also continued to make strides on the
product development and intellectual property front with the
SteraBot and SteraPack which will provide more differentiation in
our product line and a competitive advantage in the marketplace.
Management is adding executive sales division leaders and executing
a plan for all divisions to grow consistently, both domestically
and internationally, as we strive to innovate for a safer
world.”
Financial Results for the Three Months Ended
September
30,
2020 compared to
September 30,
2019
- Total net revenue was $4,292,000 compared to $1,600,000,
representing an increase of $2,692,000, or 168%.
- SteraMist® equipment-based revenues was $2,945,000 and
$669,000, respectively, representing an increase of $2,276,000 or
340%
- SteraMist® BIT Solution-based revenues was $732,000 and
$259,000, respectively, representing an increase of $473,000 or
183%
- Service-based revenue was $615,000 and $672,000, respectively,
representing a decrease of $57,000 or 8%.
- Domestic revenue was $3,446,000 and $1,288,000, respectively,
representing an increase of $2,158,000, or 168%.
- International revenue was approximately $846,000 and $312,000,
respectively, representing an increase of $534,000 or 171%.
- Gross margins were 66.1% compared to 71.3%. The lower gross
profit is attributable to the product mix in sales.
- Income from operations was $1,096,000, compared to a Loss from
operations of ($188,000), representing an increase of
$1,284,000.
- Net Income was $1,019,000, or $0.06 on a per share basis
compared to a Net loss of ($237,000), or ($0.02) on a per share
basis, representing an increase of $1,256,000.
- EBIDTA was $1,274,000 compared to an adjusted net loss of
($5,000). A table reconciling EBITDA to the appropriate GAAP
measure is included with the Company's financial information
below.
- Cash provided from operations for the nine months ended
September 30, 2020 and 2019 of $4,945,000, compared to cash used in
operations of ($573,000), respectively.
Balance sheet highlights
as of
September 30,
2020 and December 31, 2019
- Cash and cash equivalents of approximately $5,885,000 and
$897,000, representing an increase of $4,988,000.
- Working capital of $11,692,000 and ($1,266,000), representing
an increase of $12,958,000.
- Shareholders’ equity of $13,251,000 and $890,000, representing
an increase of $12,361,000.
Current Business Highlights To Date
Revenues
- Milestone reached in the third quarter of 2020 with total
revenues exceeding $21 million in a calendar year.
- Year over year growth in overall revenue through September 30th
of $16,882,000 or 376%.
- Year over year growth SteraMist® equipment revenue through
September 30th of $13,165,000 or 456%.
- Year over year growth SteraMist® BIT Solution revenue through
September 30th of $2,931,000 or 509%.
- Year over year growth in service revenue through September 30th
of $786,000 or 76%.
Business Highlights
- Increased demand on solution re-orders as disinfecting and
decontamination procedures have increased exponentially across the
world.
- Saw an increase in Hospital-Healthcare customers purchasing
multiple SteraMist units in order to deploy throughout multiple
locations and/or areas within a facility.
- Broke ground on installation of permanent fogging system into
our Frederick MD Facility.
- Continued development and testing of the “SteraBot” and launch
of pilot program at Lithuanian University Hospital.
- Continued development of SteraPack with a tentative launch set
for first quarter 2021.
- Launch of Commercial Division in response to increased demand
in Federal Government facilities and agencies, the aircraft (both
airplane and helicopter), manufacturing companies, automobile,
naval, education, retail, housing and recreation, and of course
emergency preparedness for counties and cities.
- SteraMist was featured in a United States Department of
Agriculture paper “Cold plasma-activated hydrogen peroxide aerosol
on populations of Salmonella Typhimurium and Listeria innocua and
quality changes of apple, tomato and cantaloupe during storage – A
pilot scale study” is authored by Dr. Xuetong Fan, who has
previously contributed to two prior studies regarding direct
produce application.
- Issuance of a first Australian patent protecting use of its iHP
technology, and pursuing patent rights in diverse regions of the
world, encompassing the European Union, Brazil, Mexico, Korea,
China, India, and many other countries.
- SteraMist was chosen to be a disinfection solution for the
2019-2020 PGA Champions Tour.
- Increased demand of product and services has led to the hiring
and onboarding of additional employees to assist in a wide variety
of company operations, including but not limited to accounting,
procurement, customer satisfaction, and quality control.
TOMI™ Environmental Solutions, Inc.: Innovating for
a safer world®TOMI™ Environmental Solutions, Inc.
(NASDAQ:TOMZ) is a global decontamination and infection prevention
company, providing environmental solutions for indoor surface
disinfection through the manufacturing, sales and licensing of its
premier Binary Ionization Technology® (BIT™) platform.
Invented under a defense grant in association with the Defense
Advanced Research Projects Agency (DARPA) of the U.S. Department of
Defense, BIT™ solution utilizes a low percentage Hydrogen
Peroxide as its only active ingredient to produce a fog of
ionized Hydrogen Peroxide (iHP™). Represented by the
SteraMist® brand of products, iHP™ produces a
germ-killing aerosol that works like a visual non-caustic
gas.TOMI products are designed to service a broad spectrum of
commercial structures, including, but not limited to, hospitals and
medical facilities, cruise ships, office buildings, hotel and motel
rooms, schools, restaurants, meat and produce processing
facilities, military barracks, police and fire departments, and
athletic facilities. TOMI products and services have also
been used in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols
for its clients and is a member in good standing with The American
Biological Safety Association, The American Association of Tissue
Banks, Association for Professionals in Infection Control and
Epidemiology, Society for Healthcare Epidemiology of America,
America Seed Trade Association, and The Restoration Industry
Association.
For additional information, please
visit http://www.tomimist.com/ or contact us
at info@tomimist.com.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995Certain written and oral
statements made by us may constitute “forward-looking statements”
as defined in the Private Securities Litigation Reform Act of 1995
(the “Reform Act”). Forward-looking statements are identified by
such words and phrases as “we expect,” “expected to,” “estimates,”
“estimated,” “current outlook,” “we look forward to,” “would equate
to,” “projects,” “projections,” “projected to be,” “anticipates,”
“anticipated,” “we believe,” “could be,” and other similar phrases.
All statements addressing operating performance, events, or
developments that we expect or anticipate will occur in the future,
including statements relating to revenue growth, earnings,
earnings-per-share growth, or similar projections, are
forward-looking statements within the meaning of the Reform Act.
They are forward-looking, and they should be evaluated in light of
important risk factors that could cause our actual results to
differ materially from our anticipated results. The information
provided in this document is based upon the facts and circumstances
known at this time. We undertake no obligation to update these
forward-looking statements after the date of this release.
Use of Non-GAAP Financial Measures
TOMI uses a non-GAAP financial measures in this
release. Earnings before interest, taxes, depreciation and
amortization (EBITDA) is a non-GAAP financial measure and is
intended to serve as a supplement to TOMI’s results provided in
accordance with GAAP. TOMI believes that such information may
provide its investors a better understanding of TOMI’s underlying
operational performance, business and performance trends.
Although TOMI believes that the use of non-GAAP
financial measures enhance its investors’ understanding of its
business and performance, TOMI’s use of non-GAAP financial measures
should not be considered an alternative to GAAP basis financial
measures and should be read in conjunction with the relevant GAAP
financial measures. Other companies in similar industries may
define or calculate non-GAAP financial measures differently than
TOMI, limiting their usefulness as a comparative measure.
Because of these limitations, the non-GAAP financial measure used
in this release should not be considered in isolation or as a
substitute for performance measures calculated in accordance with
GAAP. A reconciliation of the non-GAAP financial measures to the
most directly comparable GAAP measure is available in this news
release.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ASSETS |
|
|
|
|
|
|
September 30, 2020 (Unaudited) |
|
December 31, 2019 |
Cash and Cash Equivalents |
$ |
5,885,383 |
|
$ |
897,223 |
Accounts Receivable - net |
3,504,284 |
|
1,494,658 |
Other Receivables |
157,487 |
|
- |
Inventories |
4,374,500 |
|
2,315,214 |
Vendor Deposits |
333,212 |
|
141,052 |
Prepaid Expenses |
376,758 |
|
187,664 |
Total Current Assets |
14,631,624 |
|
5,035,811 |
|
|
|
|
Property and Equipment –
net |
1,111,342 |
|
1,367,864 |
|
|
|
|
Other Assets: |
|
|
|
Intangible Assets – net |
658,969 |
|
939,010 |
Operating Lease - Right of Use
Asset |
642,738 |
|
674,471 |
Capitalized Software
Development Costs - net |
62,852 |
|
94,278 |
Other Assets |
469,024 |
|
114,033 |
Total Other Assets |
1,833,583 |
|
1,821,792 |
Total Assets |
$ |
17,576,549 |
|
$ |
8,225,467 |
|
|
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
Current
Liabilities: |
|
|
Accounts Payable |
$ |
2,149,988 |
|
$ |
713,222 |
Accrued Expenses and Other Current Liabilities |
671,381 |
|
450,112 |
Accrued Officers Compensation |
40,050 |
|
- |
Accrued Interest |
- |
|
66,667 |
Current Portion of Long-Term Operating Lease |
78,723 |
|
71,510 |
Convertible Notes Payable, net of discount of $0 |
|
at December 31, 2020 |
- |
|
5,000,000 |
Total Current Liabilities |
2,940,142 |
|
6,301,511 |
|
|
|
|
Long-Term
Liabilities: |
|
|
Loan Payable |
410,700 |
|
|
Long-Term Operating Lease, Net of Current Portion |
974,311 |
|
1,034,413 |
Total Long-Term Liabilities |
1,385,011 |
|
1,034,413 |
Total Liabilities |
4,325,153 |
|
7,335,924 |
|
|
|
|
Commitments and
Contingencies |
- |
|
- |
|
|
|
|
Shareholders’
Equity: |
|
|
Cumulative Convertible Series A Preferred Stock; |
par value $0.01 per share, 1,000,000 shares authorized; 63,750
shares issued |
|
|
and outstanding at September 30, 2020 and December 31, 2019 |
638 |
|
638 |
Cumulative Convertible Series B Preferred Stock; $1,000 stated
value; |
|
|
7.5% Cumulative dividend; 4,000 shares authorized; none issued |
|
|
and outstanding at September 30, 2020 and December 31, 2019 |
- |
|
- |
Common stock; par value $0.01 per share, 250,000,000 shares
authorized; |
|
|
16,748,513 and 15,587,552 shares issued and outstanding |
|
|
at September 30, 2020 and December 31, 2019, respectively. |
167,485 |
|
155,875 |
Additional Paid-In Capital |
49,287,039 |
|
44,232,274 |
Accumulated Deficit |
(36,203,766) |
|
(43,499,244) |
Total Shareholders’ Equity |
13,251,396 |
|
889,543 |
Total Liabilities and
Shareholders’ Equity |
$ |
17,576,549 |
|
$ |
8,225,467 |
|
|
|
|
(1) Share amounts
have been retroactively restated to reflect the Company’s reverse
stock split, which was |
effected September
10, 2020. Refer to Note 11—Equity for further information. |
|
|
|
|
|
|
TOMI ENVIRONMENTAL SOLUTIONS, INC. |
CONDENSED CONSOLIDATED STATEMENT OF
OPERATIONS |
(UNAUDITED) |
|
|
|
|
|
|
|
|
|
|
|
|
For The Three Months Ended |
|
For The Nine Months Ended |
|
|
|
September 30, |
|
September 30, |
|
|
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|
|
|
|
|
|
|
|
|
|
|
Sales, net |
$ |
4,291,589 |
|
$ |
1,600,387 |
|
$ |
21,373,504 |
|
$ |
4,491,719 |
|
Cost of Sales |
1,455,568 |
|
460,008 |
|
8,484,580 |
|
1,616,680 |
|
Gross Profit |
2,836,021 |
|
1,140,379 |
|
12,888,924 |
|
2,875,039 |
|
|
|
|
|
|
|
|
|
|
|
Operating
Expenses: |
|
|
|
|
|
|
|
|
Professional Fees |
227,560 |
|
82,945 |
|
418,516 |
|
297,349 |
|
Depreciation and Amortization |
177,279 |
|
182,689 |
|
521,486 |
|
539,070 |
|
Selling Expenses |
212,624 |
|
314,110 |
|
980,096 |
|
1,274,326 |
|
Research and Development |
44,862 |
|
88,137 |
|
245,443 |
|
249,373 |
|
Equity Compensation Expense |
10,621 |
|
- |
|
307,686 |
|
87,033 |
|
Consulting Fees |
75,204 |
|
31,799 |
|
226,454 |
|
87,066 |
|
General and Administrative |
991,543 |
|
628,285 |
|
2,776,846 |
|
1,931,770 |
|
Total Operating
Expenses |
1,739,693 |
|
1,327,965 |
|
5,476,527 |
|
4,465,987 |
|
Income (loss) from
Operations |
1,096,328 |
|
(187,586) |
|
7,412,397 |
|
(1,590,948) |
|
|
|
|
|
|
|
|
|
|
|
Other Income
(Expense): |
|
|
|
|
|
|
|
|
Amortization of Debt Discounts |
- |
|
- |
|
- |
|
(17,534) |
|
Interest Income |
762 |
|
773 |
|
2,347 |
|
2,432 |
|
Interest Expense |
(790) |
|
(50,000) |
|
(42,266) |
|
(150,000) |
|
Total Other Income
(Expense) |
(28) |
|
(49,227) |
|
(39,919) |
|
(165,102) |
|
|
|
|
|
|
|
|
|
|
|
Income (loss)
before income taxes |
1,096,300 |
|
(236,813) |
|
7,372,478 |
|
(1,756,050) |
|
Provision for
Income Taxes |
77,000 |
|
- |
|
77,000 |
|
- |
|
Net Income
(loss) |
$ |
1,019,300 |
|
($236,813) |
|
$ |
7,295,478 |
|
($1,756,050) |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
Per Common Share |
|
|
|
|
|
|
|
|
Basic |
$ |
0.06 |
|
($0.02) |
|
$ |
0.44 |
|
($0.11) |
|
Diluted |
$ |
0.05 |
|
($0.02) |
|
$ |
0.40 |
|
($0.11) |
|
|
|
|
|
|
|
|
|
|
|
Basic Weighted
Average Common Shares Outstanding |
16,741,622 |
|
15,588,680 |
|
16,429,360 |
|
15,585,822 |
|
Diluted Weighted
Average Common Shares Outstanding |
18,593,255 |
|
15,588,680 |
|
18,280,993 |
|
15,585,822 |
|
|
|
|
|
|
|
|
|
|
|
(1) Share and per
share amounts have been retroactively restated to reflect the
Company’s reverse stock split, which was effected |
September 10,
2020. Refer to Note 11—Equity for further information. |
|
|
|
|
|
|
|
|
Reconciliation of Net Income to EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For The Three Months Ended |
|
For The Nine Months Ended |
|
|
|
September 30, |
|
September 30, |
|
|
|
|
2020 |
|
|
|
2019 |
|
|
|
2020 |
|
|
|
2019 |
|
|
|
|
(Unaudited) |
|
(Unaudited) |
|
(Unaudited) |
|
(Unaudited) |
Net income
(loss) |
|
$ |
1,019,300 |
|
|
$ |
(236,813) |
|
|
$ |
7,295,478 |
|
|
$ |
(1,756,050) |
|
|
|
|
|
|
|
|
|
|
|
|
Interest
Income |
|
(762) |
|
|
|
(773) |
|
|
|
(2,347) |
|
|
|
(2,432) |
|
|
Interest
Expense |
|
790 |
|
|
|
50,000 |
|
|
|
42,266 |
|
|
|
150,000 |
|
|
Depreciation and
Amortization |
|
177,279 |
|
|
|
182,689 |
|
|
|
521,486 |
|
|
|
539,070 |
|
|
Provision for
Income Taxes (Note 17) |
|
77,000 |
|
|
|
|
|
77,000 |
|
|
|
|
Other |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
17,534 |
|
|
EBITDA (Adjusted Loss) |
|
$ |
1,273,607 |
|
|
$ |
(4,897) |
|
|
$ |
7,933,883 |
|
|
$ |
(1,051,878) |
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA Margin |
|
|
30 |
% |
|
|
0 |
% |
|
|
37 |
% |
|
|
-23 |
% |
INVESTOR RELATIONS CONTACTHarold Paulhpaul@tomimist.com
TOMI Environmental Solut... (NASDAQ:TOMZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
TOMI Environmental Solut... (NASDAQ:TOMZ)
Historical Stock Chart
From Apr 2023 to Apr 2024